Studying Fat-Tissue Immune Cells in Obesity and Lean Adults
Studies fat-tissue immune cells and fat metabolism in adults with obesity.
Plain-language title generated from the registry record
Registry title: Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity
Key facts
- Where
- Columbia, United StatesSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 70, either lean or living with obesity. It studies fat tissue immune cells and how they handle fat.
- Age
- 18 to 70 years
- Sex
- All sexes
- Disease stage
- Four groups: lean (BMI 18.5 to under 25.0), metabolically normal obesity, metabolically abnormal obesity with insulin resistance and fatty liver, and metabolically abnormal obesity with type 2 diabetes. Obesity groups have BMI 30.0 to under 45.0.
- Earlier treatment
- People cannot use medications or supplements that affect glucose and lipid metabolism. The exception is certain diabetes medicines in the type 2 diabetes group.
- Biomarker or test result
- Group-specific tests: liver fat (IHTG), fasting blood glucose, blood glucose 2 hours after a 75 g sugar drink, and HbA1c.
Main reasons for not taking part
- Pregnant or breastfeeding
- Weight not stable or not sedentary before enrollment
- Use of tobacco products or too much alcohol
- Significant organ disease, such as severe chronic kidney disease or cancer
- Not meeting all inclusion criteria
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT06335771, who can take part
Where in United States
- University of Missouri School of MedicineColumbia, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Bettina Mittendorfer
- Trial code
- NCT06335771
- Record updated
- 6 August 2026
- Original description
The goal of this study is to evaluate the role of transcription factor EB (TFEB) in adipose (fat) tissue macrophages (ATM) in regulating adipose tissue and systemic metabolic function in obesity. The investigators will assess the differences in ATM lipid metabolism in people with metabolically abnormal obesity and lean individuals.Read full original descriptionShow less
Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity-Associated Diseases
The goal of this study is to evaluate the role of transcription factor EB (TFEB) in adipose (fat) tissue macrophages (ATM) in regulating adipose tissue and systemic metabolic function in obesity. The investigators will assess the differences in ATM lipid metabolism in people with metabolically abnormal obesity and lean individuals.
Both groups will have:
* screening visit * imaging (body composition testing - dual-energy x-ray absorptiometry (DEXA) scans, magnetic resonance imaging [MRI] and magnetic resonance spectroscopy [MRS] scans) * Overnight visit with intravenous infusion (IV), muscle, and fat tissue biopsies Participants with obesity will complete meetings with study team members for a weight loss intervention to achieve a 10% body weight loss.
Inclusion: age: ≥18 but ≤70 years; not pregnant or breastfeeding; weight stable and sedentary before enrollment; no use tobacco products, excessive amounts of alcohol, or dietary supplements, or medications known to or suspected to affect glucose and lipid metabolism (aside from certain medications used to treat diabetes in the metabolically abnormal obesity [MAO]-Type 2 Diabetes group); no evidence of significant organ system dysfunction or disease (e.g. chronic severe kidney disease, cancer); participants must fulfil all of the following group-specific inclusion criteria below:; Lean group:; Body mass index (BMI) ≥18.5 but <25.0 kg/m2; Intrahepatic triglyceride (IHTG) content <5%; fasting blood glucose concentration: <100 mg/dl; blood glucose concentration 2 h after a 75 g oral glucose challenge: <140 mg/dl; Hemoglobin A1C (HbA1c) <5.7 %; Metabolically normal obesity (MNO) group:; BMI ≥30.0 but <45.0 kg/m2; IHTG content <5%; fasting blood glucose concentration: <100 mg/dl; blood glucose concentration 2 h after a 75 g oral glucose challenge: <140 mg/dl; HbA1c <5.7 %; Metabolically abnormal obesity (MAO)-insulin resistance and non-alcoholic fatty liver disease (NAFLD) group:; BMI ≥30.0 but <45.0 kg/m2; IHTG content >7.5%; fasting blood glucose concentration: ≥100 but <126 mg/dl; blood glucose concentration 2 h after a 75 g oral glucose challenge: ≥140 but <200 mg/dl; HbA1c: ≥5.7 but <6.4 %; MAO-type 2 diabetes group:; BMI ≥30.0 but <45.0 kg/m2; clinical diagnosis of type 2 diabetes or fasting blood glucose concentration >126 mg/dl or blood glucose concentration 2 h after a 75 g oral glucose challenge>200 mg/dl or HbA1c >6.4 % without medication if not diagnosed and medically treated for diabetes.
Exclusion: Individuals that do not meet all inclusion Criterion.